Kornimate/medical-research-clean huggingface dataset:
study on brain structure and function of pain-related emotion disorder

Conditions: Osteoarthritis, Knee; Depressive Symptoms; Anxiety State

Summary: by the method of multi-mode magnetic resonance imaging, 5 patients with knee osteoarthritis are selected in this trial to observe the possible differences in the brain structure and function from the 5 healthy volunteers.

in this study, 5 patients with knee osteoarthritis and 5 healthy volunteers were selected. the degree of pain is evaluated via visual analogue pain scale (vas). the emotional state is evaluated by hamilton anxiety scale (hama) or hamilton depression scale (hamd). the patients and healthy volunteers who meet the include criteria are include in the research. then the spontaneous brain electrical activity is collected by multimodal brain magnetic resonance imaging technology. the spontaneous brain electrical activity is analyzed to find the differences between knee osteoarthritis patients and healthy volunteers. further analysis of resting brain functional connectivity and information exchange changes in multifunctional areas, in order to elaborate the central mechanism of pain and emotion modulation.

Eligibility criteria:
inclusion criteria: the experimental group was selected as: * meet the above diagnostic criteria. * vas scale score \> 4 points. * hama score \> 14 or hamd score \> 17 points. * agree to participate in the survey and submit an informed consent form. the control group was selected as: * healthy volunteers who exclude knee osteoarthritis. * vas scale score ≤ 4 points. * hama score ≤14 or hamd score ≤ 17 points. * agree to participate in the survey and submit an informed consent form exclusion criteria: * rheumatoid arthritis, psoriatic arthritis, gouty arthritis, bone erosion, bone tuberculosis, bone tumor patients. * clear diagnosis of traumatic meniscus, cruciate ligament, collateral ligament injury history and patients with history of knee trauma in the past six months. * have a heavier heart, brain and other medical conditions and poor overall health. * in pregnancy, pregnancy or lactation. * taking antidepressant and anxiety drugs. * participated in other clinical studies within 2 months prior to the start of the study. * the patient or his licensor is unwilling to sign a written informed consent or is unwilling to follow the research protocol.

Keywords: osteoarthritis of knee depressive symptoms anxiety state brain structure and function multi-mode magnetic resonance imaging
neurofeedback training for the treatment of substance use disorders

Conditions: Substance Use Disorders

Summary: the proposed randomized controlled trial (rct) will investigate the usefulness of electroencephalographic (eeg) biofeedback, also called neurofeedback (nf), a treatment method that can potentially prevent relapses among patients with a substance use disorder (sud) through its calming effect on the central nervous system. the study will examine whether nf can improve general well-being and quality of life (qol) and subsequently its ability to play a role in relapse prevention strategies. specifically, the effect on physical and psychological distress will be investigated.

a patient with a substance use disorder (sud) typically requires comprehensive and individualized care across different levels of service providers, from primary care to the specialist health care services. among the known threats to a prolonged remission are negative emotional states because they can trigger the urge to use drugs. an integrative approach is warranted aimed to address the physiological, psychological and social aspects of the disorder during the rehabilitation period. patients with a sud diagnosis in an outpatient clinic will be randomized to either 1) 20 sessions of symptom-based nf training in conjunction with traditional therapy or 2) conventional counseling. the primary outcome is qol at the end of treatment and at a 3 and 12 month follow-up. secondary outcome measures include alcohol and drug use, mental distress, sleep quality and cognitive function. the optimal quantity of the intervention will be assessed with a cost-benefit approach. the proposed study will provide new knowledge about how nf can be best utilized in sud treatment, potentially improving qol and relapse rates.

Eligibility criteria:
inclusion criteria: * patients with a substance use disorder referred to outpatient addiction treatment, aged \>18 of both genders. exclusion criteria: * severe psychiatric disorders (e.g. psychosis) that have not been stabilized with e.g., medication (assessed as a part of the clinical process at the clinic). severe cognitive impairment or language problems (inability to converse for interviews).
outcome after out of hospital cardiac arrest in bern, switzerland

Conditions: Resuscitation; Outcome, Fatal; Out-Of-Hospital Cardiac Arrest

Summary: sudden cardiac arrests is one of the most frequent causes of death. in switzerland every year 8000-10.000 people suffer from a cardiac arrest. the eureca one study showed regional differences in incidence and chances of survival after cardiac arrests in europe. the current european resuscitation council (erc) resuscitation guidelines 2015 recommend extracorporeal membrane oxygenation (ecmo) as treatment option for therapy refractory out-of-hospital cardiac arrests (ohca). ecmo used under cardiopulmonary resuscitation (cpr) is called ecpr (extracorporeal cpr). in the year 2018 ecpr is started to be used in bern, switzerland. this study investigates retrospectively the survival and neurologic outcome of patients after ohca in the region of bern, switzerland from 2015-2018. the data will be used as baseline for a prospective evaluation of ecpr cases. the prospective evaluation of e cpr will last from 2018 - 2022.


Eligibility criteria:
inclusion criteria: * all ohca in the region of bern, switzerland in the year 2015-2017 exclusion criteria: * if patient has previously declined to be included in a study (advance directive)
resilient occlusal and patients with temporomandibular disorder (tmd)

Conditions: Temporomandibular Disorders

Summary: the purpose of this study was to compare the effectiveness of soft occlusal splint therapy on the electromyographic activity of masticatory muscles (ateriors temporalis and masseter) before and after the application of a muscle relaxation splint. electromyography recordings from the masseter and anterior temporalis muscles were analyzed quantitatively during maximal clench, rest and mastication usual, before and after the treatment without a splint. ten patients whose chief complaint was temporomandibular disorders (tmd) were selected for the study. after the initial evaluations soft occlusal splints (muscle relaxation splints) were applied, and the patients were instructed to use the splints for four weeks. surface electromyographic recordings were taken from each patient, as clinical evaluations of tmd (index of helkimo), both evaluations before the beginning of clinical therapy and after four weeks of wearing splints. the data obtained were analyzed by wilcoxon´s and friedman´s tests.


Eligibility criteria:
inclusion criteria: * patients with clinical and/or diagnosis of tmd * with complaints of muscle disorders and / or joint pain, pain symptoms * presence of occlusal interferences * minimum of 20 functional teeth in the oral cavity with subsequent bilateral occlusion exclusion criteria: * individuals with extensive dental flaws * orthodontic treatment in progress * history of systemic diseases as advanced arthritis, diabetes and conservative and reversible treatments such as occlusal splints are recommended

Keywords: temporomandibular disorders occlusal splints electromyography tmd (muscle and joint dysfunction) masseteres e anterior temporalis muscles.
swalqol in primary hyperparathyroidism

Conditions: Hyperparathyroidism

Summary: swallow related quality of life before and after parathyroidectomy will be evaluated in patients with primary hyperparathyridism.

patients who will undergone parathyroidectomy for primary hyperparathyroidism will be included in the study. swal-qol and sf-36 forms will be used for evaluation of quality of life before and 1 month after the surgery. the change in the quality of life and swallowing related quality of life will be evaluated.

Eligibility criteria:
inclusion criteria: * no diagnosis of alzheimers disease * must be able to swallow tablets planned operation for primary hyperparathyroidism exclusion criteria: * secondary or tertiary hyperparathyroidism * insulin dependent diabetes * thyroid disease
nicotinic acid composition of hdl and arterial endothelium function in premature coronary heart disease and high hdl

Conditions: Dyslipidemias

Summary: patients with premature ischemic heart disease (pihd) and elevated levels of hdl-c present an altered composition of high-density lipoproteins (hdl) which is associated with a loss of their anti-atherogenic effects and of their arterial endothelium function. objectives: to analyse if the treatment with nicotinic acid (na)/laropiprant can correct the alterations of the hdl composition and endothelial function in patients with pihd and elevated hdl-c. methods: a total of 46 subjects with pihd who are stable in the 3 months prior to the study, who continue in treatment with statins and have elevated concentrations of hdl-c (hdl-c ≥2.0mmol/l in females and ≥1.8mmol/l in males) and an ldl-c \<100mg/dl. this is a double-blind, randomised study; after 6 weeks of lifestyle stabilisation, the subjects will be treated with na or placebo for 16 weeks. at the start and end of treatment, hdl composition will be studied through density gradient preparative ultracentrifuge separation and fblc (fast protein liquid chromatography) and through the changes in vasodilation induced by the endothelium through ultrasound. primary endpoint: change in the apoa1 content associated to treatment. secondary endpoints: variations in the change of the brachial artery diameter with reactive hyperaemia and changes in the content of other lipid and protein components of hdl including apoa2, paraoxonase, amyloid a and lcat. the changes in hdl composition and endothelial function will be assessed with an analysis of variance with repeated measurements and a 2x2 design.


Eligibility criteria:
inclusion criteria: * being male or female * age \> 25 years * have an episode of ischemic heart disease before 55 years in men and in women 65 years * serum hdl-c above the 90th percentile of the spanish population: \>=2.0mmol/l in women and \>=1.8mmol/l in men (gomez-gerique ja, et al. med clin (barc.). 1999, 113: 730-735.) * stable treatment with any statin in the past 6 weeks: simvastatin, atorvastatin, rosuvastatin, pravastatin or lovastatin. exclusion criteria: * uncontrolled hypercholesterolemia or hypertriglyceridemia, ldl-c \>2.6mmol/l or triglycerides \>2.24mmol/l * patients with an episode of ischemic heart disease in the last 3 months * patients suffering from acute or chronic inflammatory diseases in the last 3 months * treatment with fibrates or omega-3 fatty acids. * treatment with steroids or immunosuppressive drugs * patients with a contraindication to tredaptive (hypersensitivity to the active substances or any of the excipients, significant or unexplained hepatic dysfunction, active peptic ulcer, arterial bleeding). * patients treated with drugs that may interact with tredaptive (midazolam).

Keywords: dyslipemia, hdl composition
an internet-delivered intervention for parents of children with adhd

Conditions: ADHD

Summary: the aims of the present study is to investigate the efficacy of a co-designed individually-tailored internet intervention for parents of children with adhd.

attention/deficit-hyperactivity disorder is a prevalent mental health problem in children with a significant impact on children, families and society. despite the fact that evidence-based treatment exists, with pharmacologic and non-pharmacologic options available, a significant percentage of children do not have access to treatment. behavioral parent training is recommended as first line treatment for children with adhd, however, parents face numerous challenges in access, and even when they access bpt, dropout rates are high. technology could improve access to evidence-based treatments and surpass existent gaps. for instance, internet interventions are associated with moderate to large effect sizes for anxiety and depressive symptoms in adults. participants included in this study, namely parents of children diagnosed with adhd (aged 6-11 years) will be randomized either to adhdcoach intervention or treatment as usual.

Eligibility criteria:
inclusion criteria: * parent of a child diagnosed with adhd * child aged between 5-11 years * have internet access * have ability to read and write in romanian * no medication/ or stable dose of pharmacological treatment exclusion criteria: * other ongoing psychological treatment or counselling for mental health problems (currently undergoing psychotherapy or participating in a parenting program for child adhd) * recent (within the past 3 months) changes in the dose of medication * serious psychopathology requiring immediate clinical attention (e.g., severe depressive symptoms)

Keywords: internet intervention individually-tailored intervention parental distress adhd children
a feasibility study to evaluate self-harm group in inpatient settings

Conditions: Self-Injurious Behavior

Summary: the current research is being undertaken as part of a professional doctorate in clinical psychology, which aims to evaluate the feasibility of a group programme to address self-harm within 23 days, to provide evidence for a controlled trial. the intervention will include four group sessions conducted over 2 weeks, based on dialectical behavioural therapy. specifically the aims are to determine 1) means and a standard deviation for two pre and post treatment outcome measures in order to estimate sample size for the main study, 2) the need for an inpatient intervention for self-harm measured by number of participants eligible and accepting of the treatment, 3) retention of participants for 4 groups given the predicted short stays of patients on wards, and 4) the acceptability of the research process for this client group through feedback.


Eligibility criteria:
inclusion criteria: * participants will be screened by their allocated clinician and included if they are aged between 18-65 * admitted to hospital * have a history of or engaged in at least one episode of self-harm, iv) have capacity to understand the information sheet. exclusion criteria: * participants will be screened by clinicians and they will exclude people if i) they are non-english speakers (due to translation costs) * they lack the capacity to give informed consent (assessed by their key clinician) * their symptoms prevent them from concentrating for an hour at a time (i.e. severe thought disorder), and therefore not benefiting from the group (assessed by their key clinician)
effect of electroacupuncture on sap with mods

Conditions: Severe Acute Pancreatitis

Summary: 1. title: effect of electroacupuncture on severe acute pancreatitis with multiple organ disfunction syndrome patients: a randomized clinical trial 2. research center: single center 3. design of the research: a randomized, double-blind and parallel controlled study 4. object of the research: the patients over 18 years that met the criteria of sap and with more than 2 organs failure. 5. sample size of the research: a total of 220patients,110 cases in each group 6. interventions: the acupuncture points for electroacupuncture are zusanli(st36), xiajuxu(st39), hegu(li4), neiguan(pc6) points . participants in the treatment group underwent 30 minutes acupuncture (0.30mm×70mm) at above points once a day for seven days. after"deqi",electroacupuncture stimulation apparatus (hans g6805-2, huayi co, shanghai, china) is connected and maintained the end of treatment. participants in the control group received shallow needling (0.30mm×25mm) at nonacupoints (located 1 inch beside acupoints). specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no "deqi" without actual current output. 7. aim of the research: to investigate the effect of electroacupuncture on severe acute pancreatitis with multiple organ disfunction syndrome. 8. outcome #primary outcomes: all-cause 28-day mortality. secondary outcomes: duration of organ failure; the incidence of pancreatic necrotic tissue infection; time for enteral nutrition to reach the standard (30kcal/kg); mechanical ventilation time; length of hospital stay 9. the estimated duration of the study#2 years.

this study is a randomized, double-blinded, placebo controlled and long-term follow-up design. in this study, zusanli(st36), xiajuxu(st39), hegu(li4), neiguan(pc6) were selected for electroacupuncture treatment, accompanied with evaluating the effects on 28-day mortality in sap patients with mods, as well as the duration of organ failure, the incidence of pancreatic necrotic tissue infection and length of hospital stay . to clarify the effect of electroacupuncture on sap patients with mods is of great significance to the clinical applications and popularization of traditional acupuncture treatment across the world.

Eligibility criteria:
inclusion criteria: 1. meet the diagnosis of severe acute pancreatitis (atlanta diagnostic criteria), within 1 week of onset 2. combine 2 or more organ failures at the same time, and the duration is greater than 48h 3. age ≥18 years old; 4. obtain informed consent. exclusion criteria: 1. pregnancy pancreatitis; 2. patients who have undergone percutaneous puncture or surgical drainage before admission, and have undergone surgical decompression due to early abdominal hypertension; 3. patients with a history of chronic organ dysfunction (such as uremia, copd, liver cirrhosis, heart failure, etc.). 4. those who have a medical history of acupuncture and moxibustion or are not sensitive to acupuncture and moxibustion. 5. those who refuse to participate in the research

Keywords: severe acute pancreatitis multiple organ disfunction syndrome
the therapeutic effect of bet in com with etd

Conditions: Balloon Eustachian Tuboplasty

Summary: currently, surgical treatment of patients with chronic otitis media is one of the most important treatment methods. however, the current results show that some patients with eustachian tube dysfunction can't reconstruct the gas-containing structure of the middle ear after operation. this is a randomized controlled trial that aims to evaluate the therapeutic effect of balloon eustachian tuboplasty (bet) for the treatment in chronic otitis media (com) with eustachian tube dysfunction (etd). this future study will aim to address the question: does bet gain better recovery of auditory function and lower recurrence rate in chronic otitis media with eustachian tube dysfunction?


Eligibility criteria:
inclusion criteria: 1. patients who need tympanoplasty, with clear diagnosis of chronic otitis media, middle ear cholesteatoma; 2. patients with eustachian tube dysfunction using tmm; 3. subjects or their legal representatives can understand the purpose of the study, show sufficient compliance with the research protocol, and sign the informed consent form. exclusion criteria: 1. secondary chronic otitis media (after head and neck cancer radiotherapy); 2. ipsilateral ear recurrence after surgical treatment, requiring secondary surgery; 3. two tympanoplasty surgery; 4. typical allergic rhinitis, nasal endoscopy or imaging studies suggest chronic rhinosinusitis, nasal polyps and other short-term eustachian tube function of a greater impact on the disease; 5. poor general health, with severe liver and kidney dysfunction, coagulation disorders, cardiovascular disease, neurological diseases can not tolerate surgery.
safety and efficacy of bone marrow cell transplantation in humans myocardial infarction

Conditions: Acute Myocardial Infarction

Summary: we will study in a prospective randomised fashion 50 patients who will be treated by intracoronary transplantation of autologous, mononuclear bone marrow cells (bmcs) in addition to standard therapy after mi or standard therapy. after standard therapy for acute mi, 10 patients were transplanted with autologous mononuclear bmcs via a balloon catheter placed into the infarct-related artery during balloon dilatation (percutaneous transluminal coronary angioplasty). another 10 patients with acute mi were treated by standard therapy alone. after

experimental and clinical data suggest that bone marrow-derived cells may contribute to the healing of myocardial infarction (mi).

Eligibility criteria:
inclusion criteria: * recent acute transmural anterior myocardial infarction, (in agreement with who) * single left anterior descending coronary artery disease * \<72 hour from the origin of symptoms * successful primary angioplasty of the culprit lesion exclusion criteria: * screening \>72 hours after infarction, * cardiac shock, severe comorbidity, alcohol or drug dependency * severe comorbidity (dm,renal or liver insufficiency) * potential child bearing woman * inability to provide informed consent

Keywords: bone marrow, cell transplantation, stem cells, ptca
erlotinib concurrent with radiation therapy in non-small-cell lung cancer

Conditions: Carcinoma, Non-Small Cell Lung

Summary: the purpose of this study is to determine the safety and efficacy of the concurrent use of erlotinib and radiation therapy in the treatment of locally advanced non-small lung cancer.

non-small cell lung cancer (nsclc) is still the leading cause of cancer death world-wide. radiation therapy (rt) is one of the most important treatment choices in locally advanced nsclc. combination of rt and chemotherapy could improve treatment outcomes. however, the combined modality could not be used in many patients due to severe toxicities. egfr-tki shows great efficacy in the treatment of nsclc, and many phase i/ii studies established its safety in combination with rt. this phase ii study is to further evaluate the efficacy and safety of the combination of rt and erlotinib in the treatment of locally advanced nsclc. eligible patients include patients with stage iiia/iiib nsclc, who are not suitable for or refused to receive concurrent chemoradiotherapy. eligible patients will receive oral erlotinib (150mg qd)throughout the course of thoracic rt (60-70 gy). the primary endpoint is progression free survival and the second endpoints are overall survival and any grade iii and above toxicities. we are going to recruit 50 patients for this study.

Eligibility criteria:
inclusion criteria: * aged 18-70 years， * patients with stage iiia-iiib nsclc * adequate hematologic (wbc and platelet counts within normal limits), hepatic (total bilirubin level \ = 50ml/min) functions * no history of chemotherapy or less than 4 cycles neoadjuvant chemotherapy * can not tolerate or refuse concurrent chemoradiotherapy * no history of thoracic rt * written informed consent obtained exclusion criteria: * with other malignancy * with severe cardiopulmonary disease * compromised liver or renal function that could not tolerate the combined therapy * received thoracic rt before * pregnant or breast-feeding women * present with active infection * uncontrolled diabetes * concurrent use of other anti-cancer agents

Keywords: non-small-cell lung cancer radiation therapy epidermal growth factor receptor tyrosine kinase inhibitor